Developer docs
API playgroundTry for free, no card

Search company profiles

PetDx

Full company profile

uuid0000fks

Namestring
PetDx
Websiteurl
petdx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

PetDx is a veterinary molecular diagnostics company founded in 2019 and headquartered in La Jolla, California, focused on the early detection of cancer in dogs. The company develops and commercializes OncoK9, a proprietary liquid biopsy assay that analyzes genomic markers in canine blood samples to identify cancer signals non-invasively. The core product is positioned as an alternative to traditional surgical biopsy for initial cancer screening, with stated sensitivity for early-stage detection in dogs.

PetDx sells its diagnostic testing services primarily to veterinary clinics and animal hospitals, which order and administer the OncoK9 test for canine patients; pet owners are an indirect secondary segment accessed via veterinary referral. Revenue is generated through one-time testing fees on a license-style basis, with pricing not publicly disclosed. Distribution occurs through direct sales to veterinary practices and a global distributor network intended to broaden reach into additional clinics. The company is led by a co-founder-heavy management team spanning medical (Andi Flory, CMO), scientific (Dana Tsui, CSO), technology (Ilya Chorny, CTO), and operational/commercial functions, with Alejandro Bernal serving as CEO and President.

The company has raised approximately $72 million across two disclosed funding rounds: a $10M Series A in June 2020 led by Friedman BioVentures with Petco and TCA Venture Group, and a $62M Series B in December 2021 led by Longview Asset Management with participation from Aperture Venture Partners, Declaration Partners, Friedman BioVentures, K4 Group, LabCorp, Torch Capital, and Valor Equity Partners. Series B proceeds were earmarked for OncoK9 expansion, R&D acceleration, testing capacity scaling, and strengthening clinic and distributor partnerships. The company remains privately held with no disclosed revenue.

Short descriptiontext

PetDx is a veterinary molecular diagnostics company that develops and commercializes OncoK9, a proprietary liquid biopsy assay for early cancer detection in dogs, serving veterinary clinics and pet owners via a distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
veterinary diagnostics, canine cancer detection, liquid biopsy testing, molecular diagnostics, veterinary screening assays
Industry2 codes
PRIMARYHLAMADAE
Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
SECONDARYHLAMADAJ
Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Veterinary Diagnostic Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Veterinary Diagnostic Testing Services
TypeOne Time License
Description

PetDx generates revenue through its OncoK9 cancer detection test sold to veterinary clinics and potentially directly to pet owners through veterinary referral.

genomeweb.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1OncoK9
Description

Cancer detection assay for canine cancer screening

genomeweb.com
Core offering1 text field

PetDx develops and commercializes the OncoK9 cancer detection assay, a non-invasive blood-based liquid biopsy test designed for early detection of cancer in dogs. The assay analyzes genomic markers from a canine blood sample to identify cancer signals, providing veterinarians with a screening tool that can be used either in higher-risk breeds or for pets showing concerning symptoms. PetDx delivers the test through veterinary clinics and a distributor network.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

PetDx is a veterinary diagnostics company that offers a focused portfolio centered on canine cancer detection. The company's primary product is the OncoK9 assay, a blood-based test designed to detect cancer in dogs. The company uses this technology to provide diagnostic services to veterinary clinics and aims to expand testing capacity and strengthen partnerships with clinics and distributors.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IDEXX is the dominant veterinary diagnostics company, offering reference lab services, in-clinic analyzers, and a broad menu of tests across species. It is a broad incumbent in the same veterinary diagnostics category in which PetDx operates, with established distribution into virtually every US veterinary practice.

TypeBroad incumbent
Description

Antech is a leading veterinary reference laboratory network, owned by Mars Petcare, serving veterinary clinics with routine and specialty diagnostics. It overlaps directly with PetDx on the canine cancer screening use case and benefits from deep clinic relationships and bundled test menus.

TypeBroad incumbent
Description

Zoetis is the largest global animal health company and offers diagnostic products (e.g., Vetscan) plus genetic testing (via the Basepaws acquisition). It is a broad incumbent competing for veterinary diagnostic spend, including genetic and specialty testing that overlaps with PetDx's molecular approach.

TypeDirect peer
Description

Embark is a canine genetic testing company offering DNA-based health and breed tests. While focused on inherited disease and breed genetics rather than cancer liquid biopsy, Embark is a direct peer in canine molecular diagnostics sold through breeders, owners, and veterinary channels.

TypeDirect peer
Description

Wisdom Panel, part of Mars Petcare, is a leading canine and feline genetic testing brand. It is a direct peer in companion-animal molecular diagnostics, with overlapping distribution through veterinary clinics and direct-to-consumer channels.

TypeDirect peer
Description

Basepaws provides feline and canine genetic and oral-health screening tests and is now part of Zoetis. It is a direct peer offering molecular diagnostics for companion animals, with comparable product positioning around early detection of disease risk.

TypeEmerging player
Description

Paw Print Genetics offers genetic testing for hereditary diseases and traits across multiple companion animal species. It is an emerging player in veterinary molecular diagnostics with overlapping technology (DNA-based assays) and channel (veterinary clinics, breeders), but does not currently focus on liquid-biopsy cancer detection.

TypeEmerging player
Description

Volition Veterinary is developing blood-based nucleomics tests for cancer and other conditions in companion animals. It is an emerging peer pursuing liquid-biopsy cancer diagnostics in dogs, with overlapping product concept and veterinary channel strategy.

TypeOthers
Description

LabCorp is a strategic investor in PetDx and a leading human clinical and anatomic pathology lab with extensive oncology diagnostics capabilities. It is a thematically related partner that provides infrastructure, scientific, and channel know-how transferable to veterinary oncology.

10Petco Health and Wellness
TypeOthers
Description

Petco is both an investor in PetDx and a leading US pet specialty retailer with growing veterinary services (Vital Care, Thrive). It is a strategic ecosystem participant that can serve as a distribution and awareness channel for canine cancer screening.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PetDx

Veterinary Diagnostic Servicespetdx.com

PetDx is a veterinary molecular diagnostics company that develops and commercializes OncoK9, a proprietary liquid biopsy assay for early cancer detection in dogs, serving veterinary clinics and pet owners via a distributor network.

What PetDx does

PetDx is a veterinary molecular diagnostics company founded in 2019 and headquartered in La Jolla, California, focused on the early detection of cancer in dogs. The company develops and commercializes OncoK9, a proprietary liquid biopsy assay that analyzes genomic markers in canine blood samples to identify cancer signals non-invasively. The core product is positioned as an alternative to traditional surgical biopsy for initial cancer screening, with stated sensitivity for early-stage detection in dogs.

PetDx sells its diagnostic testing services primarily to veterinary clinics and animal hospitals, which order and administer the OncoK9 test for canine patients; pet owners are an indirect secondary segment accessed via veterinary referral. Revenue is generated through one-time testing fees on a license-style basis, with pricing not publicly disclosed. Distribution occurs through direct sales to veterinary practices and a global distributor network intended to broaden reach into additional clinics. The company is led by a co-founder-heavy management team spanning medical (Andi Flory, CMO), scientific (Dana Tsui, CSO), technology (Ilya Chorny, CTO), and operational/commercial functions, with Alejandro Bernal serving as CEO and President.

The company has raised approximately $72 million across two disclosed funding rounds: a $10M Series A in June 2020 led by Friedman BioVentures with Petco and TCA Venture Group, and a $62M Series B in December 2021 led by Longview Asset Management with participation from Aperture Venture Partners, Declaration Partners, Friedman BioVentures, K4 Group, LabCorp, Torch Capital, and Valor Equity Partners. Series B proceeds were earmarked for OncoK9 expansion, R&D acceleration, testing capacity scaling, and strengthening clinic and distributor partnerships. The company remains privately held with no disclosed revenue.

PetDx firmographics

Firmographics
Name
PetDx
Website
https://petdx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
PetDx is a veterinary molecular diagnostics company that develops and commercializes OncoK9, a proprietary liquid biopsy assay for early cancer detection in dogs, serving veterinary clinics and pet owners via a distributor network.
Ownership category
akta.pro rank

PetDx industry classification

Industry
Product category
Veterinary Diagnostic Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAMADAE
Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
SECONDARYHLAMADAJ
Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)

Keywords

  • Veterinary diagnostics
  • Canine cancer detection
  • Liquid biopsy testing
  • Molecular diagnostics
  • Veterinary screening assays

Where PetDx is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

PetDx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Veterinary Diagnostic Testing Services: PetDx generates revenue through its OncoK9 cancer detection test sold to veterinary clinics and potentially directly to pet owners through veterinary referral.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

PetDx product offering

Product offering

Core offering

PetDx develops and commercializes the OncoK9 cancer detection assay, a non-invasive blood-based liquid biopsy test designed for early detection of cancer in dogs. The assay analyzes genomic markers from a canine blood sample to identify cancer signals, providing veterinarians with a screening tool that can be used either in higher-risk breeds or for pets showing concerning symptoms. PetDx delivers the test through veterinary clinics and a distributor network.

Product overview

PetDx is a veterinary diagnostics company that offers a focused portfolio centered on canine cancer detection. The company's primary product is the OncoK9 assay, a blood-based test designed to detect cancer in dogs. The company uses this technology to provide diagnostic services to veterinary clinics and aims to expand testing capacity and strengthen partnerships with clinics and distributors.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoK9: Cancer detection assay for canine cancer screening

Companies that use PetDx

Customer profile

Segments2 records

Ideal customer profiles2 records

PetDx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

PetDx partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

PetDx competitors and assessment

Company assessment

Broad incumbents

  • IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company, offering reference lab services, in-clinic analyzers, and a broad menu of tests across species. It is a broad incumbent in the same veterinary diagnostics category in which PetDx operates, with established distribution into virtually every US veterinary practice.
  • Antech Diagnostics: Antech is a leading veterinary reference laboratory network, owned by Mars Petcare, serving veterinary clinics with routine and specialty diagnostics. It overlaps directly with PetDx on the canine cancer screening use case and benefits from deep clinic relationships and bundled test menus.
  • Zoetis Diagnostics: Zoetis is the largest global animal health company and offers diagnostic products (e.g., Vetscan) plus genetic testing (via the Basepaws acquisition). It is a broad incumbent competing for veterinary diagnostic spend, including genetic and specialty testing that overlaps with PetDx's molecular approach.

Direct peers

  • Embark Veterinary: Embark is a canine genetic testing company offering DNA-based health and breed tests. While focused on inherited disease and breed genetics rather than cancer liquid biopsy, Embark is a direct peer in canine molecular diagnostics sold through breeders, owners, and veterinary channels.
  • Wisdom Panel (Wisdom Health): Wisdom Panel, part of Mars Petcare, is a leading canine and feline genetic testing brand. It is a direct peer in companion-animal molecular diagnostics, with overlapping distribution through veterinary clinics and direct-to-consumer channels.
  • Basepaws (Zoetis): Basepaws provides feline and canine genetic and oral-health screening tests and is now part of Zoetis. It is a direct peer offering molecular diagnostics for companion animals, with comparable product positioning around early detection of disease risk.

Emerging players

  • Paw Print Genetics: Paw Print Genetics offers genetic testing for hereditary diseases and traits across multiple companion animal species. It is an emerging player in veterinary molecular diagnostics with overlapping technology (DNA-based assays) and channel (veterinary clinics, breeders), but does not currently focus on liquid-biopsy cancer detection.
  • Volition Veterinary: Volition Veterinary is developing blood-based nucleomics tests for cancer and other conditions in companion animals. It is an emerging peer pursuing liquid-biopsy cancer diagnostics in dogs, with overlapping product concept and veterinary channel strategy.

Others

  • Labcorp (LabCorp Drug Development / Oncology): LabCorp is a strategic investor in PetDx and a leading human clinical and anatomic pathology lab with extensive oncology diagnostics capabilities. It is a thematically related partner that provides infrastructure, scientific, and channel know-how transferable to veterinary oncology.
  • Petco Health and Wellness: Petco is both an investor in PetDx and a leading US pet specialty retailer with growing veterinary services (Vital Care, Thrive). It is a strategic ecosystem participant that can serve as a distribution and awareness channel for canine cancer screening.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

PetDx social profiles

Digital presence

PetDx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PetDx leadership team

Management profile

Number of profiles

Profiles9 records

PetDx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PetDx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PetDx

What does PetDx do?

PetDx develops and commercializes the OncoK9 cancer detection assay, a non-invasive blood-based liquid biopsy test designed for early detection of cancer in dogs. The assay analyzes genomic markers from a canine blood sample to identify cancer signals, providing veterinarians with a screening tool that can be used either in higher-risk breeds or for pets showing concerning symptoms. PetDx delivers the test through veterinary clinics and a distributor network.

Is PetDx a public or private company?

PetDx is a private company. It is classified as venture growth investor backed and is currently operating.

When was PetDx founded?

PetDx was founded in 2019. It employs 11 to 50 people.

Where is PetDx based?

PetDx is headquartered in San Diego, United States, in the North America region.

How does PetDx make money?

One revenue line is on record: veterinary Diagnostic Testing Services.

Who are PetDx's main competitors?

Broad incumbents on record are IDEXX Laboratories, Antech Diagnostics and Zoetis Diagnostics. Direct peers are Embark Veterinary, Wisdom Panel (Wisdom Health) and Basepaws (Zoetis). Emerging players are Paw Print Genetics and Volition Veterinary. Others are Labcorp (LabCorp Drug Development / Oncology) and Petco Health and Wellness.

Does PetDx have an API?

No public API is recorded for PetDx.

What industry is PetDx in?

PetDx's product category is Veterinary Diagnostic Services. Its primary akta.pro industry code is HLAMADAE, Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology), with a secondary code of HLAMADAJ, Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Grand View ResearchVeterinary Precision Medicine Market Size Report, 2026-2033The global veterinary precision medicine market was valued at $558.9 million in 2025 and is projected to grow to $1.5 billion by 2033, at a CAGR of 13.5%, driven by rising companion animal cancer prevalence, pet humanization trends, and AI/ML advances in bioinformatics. North America held the largest regional share at 44.6% in 2025, with the diagnostic and pathology segment commanding 39.3% of market revenue and oncology representing the dominant therapeutic area. Key market participants including ImpriMed, FidoCure, Anivive Lifesciences, PetDx, LEAH Labs, and Elias Animal Health are expanding AI-driven drug response prediction, genomic profiling, and cell therapy services, with Asia Pacific identified as the fastest-growing region for companion animal precision oncology.Grand View ResearchVeterinary Oncology Diagnostics Market Size Report, 2030Grand View Research published a market analysis report projecting the global veterinary oncology diagnostics market to grow from USD 2.17 billion in 2024 to USD 3.45 billion by 2030, driven by rising pet cancer prevalence and advancements in early detection technologies. Key industry players such as VolitionRx, Antech, IDEXX, and PetDx are expanding their product portfolios through new test launches and strategic partnerships to capture market share in regions including North America, Europe, and Asia Pacific.PR NewswireNovel lower-cost blood test for cancer screening in dogs validated in large clinical study by PetDxPetDx published a study in JAVMA validating its OncoK9 Screen blood test for seven common canine cancers, showing over 70% sensitivity and a false-positive rate under 1.5%. The test uses cell-free DNA quantification and is faster and cheaper than the company's flagship OncoK9 Dx, aiming to make early cancer detection more accessible.PR NewswireOncoK9® Liquid Biopsy Test Can be Used for Cancer Monitoring in Dogs Across a Variety of Cancer Types, AJVR Publication ShowsA study published in the American Journal of Veterinary Research found that PetDx's OncoK9 blood test detects residual disease and cancer recurrence in dogs treated for 12 cancer types. Among patients with clinical recurrence, 82% had a Cancer Signal Detected result prior to recurrence, with a median lead time over 5 months.PR NewswirePerformance of OncoK9® in Real-World Veterinary Practice Mirrors Clinical Validation StudyPetDx published a peer-reviewed study in the Journal of the American Veterinary Medical Association showing that their OncoK9 liquid biopsy test for early cancer detection in dogs performs consistently in real-world veterinary practice as it did in the original clinical validation study. The study examined 1,500 consecutive blood samples and found that patients receiving a Cancer Signal Detected result were subsequently diagnosed with cancer by a veterinarian in nearly 90% of cases, with most diagnoses achieved within two weeks using standard clinic tools. When used as a screening test on high-risk asymptomatic dogs, OncoK9 detected 26 cancer types, including half that are not commonly found on wellness exams.PR NewswirePetDx Appoints Alejandro Bernal as its New President and Chief Executive OfficerPetDx, a San Diego-based molecular diagnostics company, announced the appointment of Alejandro Bernal as its new President and Chief Executive Officer, succeeding founder Daniel S. Grosu who will continue as Chairman of the Board. Bernal is an animal health industry veteran who previously served as President for Mars Veterinary Health International and Global Diagnostics and spent 17 years at Zoetis. The company stated that Bernal's appointment will guide PetDx through its next phase of growth, leveraging his experience in driving transformative investment agendas and building differentiated businesses in the veterinary sector.PR NewswireOncoK9 Liquid Biopsy Test Can Enhance Cancer Monitoring in Dogs, New Results ShowPetDx released a white paper demonstrating that its OncoK9 liquid biopsy test for dogs can enhance cancer monitoring by detecting residual disease after surgery and cancer recurrence following therapy. The CANDiD study, involving over 200 canine patients across more than 500 follow-up visits, showed over 95% concordance between OncoK9 results and clinical disease status, with the test detecting molecular recurrence prior to clinical recurrence in 37% of cases with a median lead time exceeding two months. Veterinarians can order the expanded OncoK9 test for cancer monitoring starting in February 2023.PR NewswireOncoK9®, the Pioneering Blood-Based Early Cancer Detection Test for Dogs, Now Available in Asia Through Asia Veterinary DiagnosticsPetDx® has launched its OncoK9® blood-based early cancer detection test for dogs in five Asian markets—Hong Kong, Singapore, Malaysia, South Korea, and Cambodia—through a distribution partnership with Asia Veterinary Diagnostics, marking the first expansion of the test beyond North America. The multi-cancer early detection test, validated through the CANDiD study involving over 1,000 dogs across more than 40 clinical sites, can detect 30 types of canine cancer with a simple blood draw, achieving 85.4% sensitivity and 98.5% specificity. PetDx indicated that expanding access to this non-invasive screening tool is a top priority as it seeks to grow its international footprint.PR NewswirePetDx to Present at Stifel 2022 Jaws & Paws ConferencePetDx, a San Diego-based molecular diagnostics company specializing in liquid biopsy for pets, announced its participation in the Stifel 2022 Jaws & Paws Conference in New York City on June 1, 2022, where company leaders will present and discuss the market opportunity for its OncoK9 multi-cancer early detection test for dogs. The presentation follows the recent publication of the landmark CANcer Detection in Dogs (CANDiD) study and will cover the development and commercialization of the company's NGS-based blood test for canine cancer detection. The live audio webcast will be accessible to investors and industry stakeholders during the event.PR NewswirePetDx® Announces Publication of Landmark Clinical Validation Study for OncoK9®, Its Pioneering Multi-Cancer Early Detection Test for Dogs Using Next-Generation SequencingPetDx announced the publication of the CANDiD study in PLOS ONE, the largest clinical validation study in veterinary cancer diagnostics, which validated its OncoK9 multi-cancer early detection test for dogs using next-generation sequencing of blood-derived DNA. The study enrolled over 1,000 client-owned dogs across more than 40 clinical sites in six countries, demonstrating 85.4% sensitivity for three of the most aggressive canine cancers and 98.5% overall specificity. The test, launched commercially in 2021, is now available through PetDx and IDEXX Reference Laboratories at veterinary practices across the United States and Canada, with further studies underway for additional use cases including minimal residual disease detection and treatment response monitoring.